Rapport Therapeutics, Inc Common Stock

Yahoo Finance • 10 days ago

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story

Yahoo Finance • 3 months ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 3 months ago

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rapport Therapeutics, Inc. BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development o... Full story

Yahoo Finance • 4 months ago

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity RAP-219 demonstrated... Full story

Yahoo Finance • 6 months ago

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precisio... Full story

Yahoo Finance • 6 months ago

QuantumScape rallies as Seeking Alpha analyst pitches the upside

[Financial advisor interacts with a digital interface displaying machine learning data insights.] QuantumScape Corporation (NYSE:QS [https://seekingalpha.com/symbol/QS]) rallied in morning trading on Thursday as it took back ground lost o... Full story

Yahoo Finance • 7 months ago

Rapport Therapeutics prices $250M stock at $26 per share

* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) priced [https://seekingalpha.com/pr/20227241-rapport-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 9.62M shares at a p... Full story

Yahoo Finance • 7 months ago

Rapport Announces Pricing of Public Offering of Common Stock

BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precisio... Full story

Yahoo Finance • 7 months ago

Let's take a look at the stocks that are in motion in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 7 months ago

Stocks Settle Higher as Bond Yields Fall and Chip Makers Climb

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.46%.  September E-mini S&P futures (ESU25) rose +0.25%, and Sept... Full story

Yahoo Finance • 7 months ago

Rapport launches proposed public offering of common stock

* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) has commenced an underwritten public offering of $250M of shares of its common stock. * RAPP -5.61% after hours to $29.76. * Source: Press Release [https://s... Full story

Yahoo Finance • 7 months ago

Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT RAPP [ht... Full story

Yahoo Finance • 7 months ago

10 most overbought S&P 500 stocks ahead of PPI and CPI data

[Top 10 alphabet letters top view on purple glitter background] Wall Street has started the week on a cautious tone as investors flag the most overbought stocks in the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]), while broader... Full story

Yahoo Finance • 7 months ago

Stocks Supported by Hopes of Fed Rate Cuts

The S&P 500 Index ($SPX) (SPY) today is up +0.35%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.08%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.79%.  September E-mini S&P futures (ESU25) are up +0.35%, and September E-mini N... Full story

Yahoo Finance • 7 months ago

Top stock movements in today's session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT RAPP [https://www.chartmill.com/stock/quote/RAPP/profile] 111.0%... Full story

Yahoo Finance • 7 months ago

Rapport Therapeutics: Phase 2a Trial Of RAP-219 Meets Primary Endpoint

(RTTNews) - Rapport Therapeutics (RAPP) announced that the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint, demonstrating a statistically significant reduction in long episod... Full story

Yahoo Finance • 7 months ago

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatme... Full story

Yahoo Finance • 7 months ago

Biggest stock movers Monday: RAPP, HOUR, IDYA, NFE and more

[Shot of a handsome young businessman using a digital tablet while working late in his office] PeopleImages U.S. stock futures edged up on Monday as investors looked ahead to two important inflation reports this week, that will shape expe... Full story

Yahoo Finance • 7 months ago

Rapport Therapeutics To Report Epilepsy Trial Results On Monday - Will The Stock Surge Or Tumble?

(RTTNews) - Rapport Therapeutics Inc. (RAPP), a clinical-stage biopharmaceutical company developing drugs for patients with neurological or psychiatric disorders, has a key clinical trial catalyst to watch on Monday, September 8, 2025. Th... Full story

Yahoo Finance • 7 months ago

Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset

[Financial chart with moving up arrow graph in stock market on blue color background] * Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) surged 23% in after-hours trading Friday after announcing that it would re... Full story